Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6610)	7/1/1998 6:23:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

I find it most interesting that on the cnto website, their "timeline of corporate history" does not even mention ha1a. I personally dont see any great value there except the anti-TNF monoclonal (if it works). Of course the antiTNF strategy point to possibilities with bpi or lbp or such in cd14 cascade. Since crohns is "probably" infection mediated, and tnf is implicated,and anca to bpi are present, one would have to assume sooner or later attention would turn to bpi,lactoferrin, etc. as both tnf modifiers (amonng other things, antiinfectives, and bpi replenishers. Perhaps. Just talking to myself and typing. Later. All IMO, all theory. All disclaimers